Trends and advances in tumor immunology and lung cancer immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trends and advances in tumor immunology and lung cancer immunotherapy
Authors
Keywords
Lung cancer, Tumor immunology, Immunotherapy, Cancer vaccines, Clinical trials, Immune checkpoint inhibitors
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 35, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-29
DOI
10.1186/s13046-016-0439-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
- (2016) David Planchard et al. Clinical Lung Cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
- (2016) Scott Antonia et al. Cancer Immunology Research
- Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer
- (2015) F. Vegran et al. CANCER RESEARCH
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
- (2015) B. Besse et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-cell exhaustion in the tumor microenvironment
- (2015) Y Jiang et al. Cell Death & Disease
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
- (2014) H.-J. Kim et al. Cancer Immunology Research
- How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
- (2014) Ole Audun Werner Haabeth et al. Frontiers in Immunology
- Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
- (2013) Alan G. Ramsay BRITISH JOURNAL OF HAEMATOLOGY
- Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results
- (2013) Johan Vansteenkiste et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- MAGE-A3-specific anticancer immunotherapy in the clinical practice
- (2013) Vincent G. Brichard et al. OncoImmunology
- TGF-β signalling and its role in cancer progression and metastasis
- (2012) Yvette Drabsch et al. CANCER AND METASTASIS REVIEWS
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression
- (2012) K. Oleinika et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer and Innate Immune System Interactions
- (2012) Yanan Liu et al. JOURNAL OF IMMUNOTHERAPY
- Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)
- (2012) Nasrollah Erfani et al. LUNG CANCER
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix
- (2012) Hélène Salmon et al. OncoImmunology
- TG4010
- (2012) Jean-Marc Limacher et al. OncoImmunology
- Involvement of STAT3 in immune evasion during lung tumorigenesis
- (2012) Hiroshi Kida et al. OncoImmunology
- Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
- (2011) L. Decoster et al. ANNALS OF ONCOLOGY
- Follicular Helper CD4 T Cells (TFH)
- (2011) Shane Crotty Annual Review of Immunology
- Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
- (2011) A. M. Lesokhin et al. CANCER RESEARCH
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists
- (2011) Peter Mazzone et al. RESPIRATORY MEDICINE
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
- (2010) R. Bos et al. CANCER RESEARCH
- Granzymes in cancer and immunity
- (2010) S P Cullen et al. CELL DEATH AND DIFFERENTIATION
- Transforming growth factor-β and the hallmarks of cancer
- (2010) Maozhen Tian et al. CELLULAR SIGNALLING
- PD-L1 expression on tolerogenic APCs is controlled by STAT-3
- (2010) Sabine J. Wölfle et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia
- (2010) Ana P. Gonzalez-Rodriguez et al. LEUKEMIA & LYMPHOMA
- Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells
- (2010) S Bafna et al. ONCOGENE
- The Prevalence of FOXP3+ Regulatory T-Cells in Peripheral Blood of Patients with NSCLC
- (2009) Liu Li et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Natural killer cell-based immunotherapy in cancer: current insights and future prospects
- (2009) T. Sutlu et al. JOURNAL OF INTERNAL MEDICINE
- Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells
- (2009) Sara Trifari et al. NATURE IMMUNOLOGY
- Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
- (2009) F R Hirsch et al. ONCOGENE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Alteration of the immunological synapse in lung cancer: a microenvironmental approach
- (2008) S. Derniame et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pattern recognition receptors in the immune response against dying cells
- (2008) Pascale Jeannin et al. CURRENT OPINION IN IMMUNOLOGY
- Strategies used for MUC1 immunotherapy: preclinical studies
- (2008) Choon-Kit Tang et al. Expert Review of Vaccines
- The anticancer immune response: indispensable for therapeutic success?
- (2008) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer
- (2008) Elia Neninger Vinageras et al. JOURNAL OF CLINICAL ONCOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started